EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Prognostic Relevance of Surface α-Enolase (ENO1) in Patients With Lung Adenocarcinoma

YU-SEN LIN, TE-HONG CHEN, YUAN-YAO TSAI, TAO-WEI KE, CHI-HSIEN HUANG, CHIA-YU TSAI, WILLIAM TZU-LIANG CHEN, K.S. CLIFFORD CHAO, KEVIN CHIH-YANG HUANG

Cancer Diagnosis & Prognosis · 2026-11-01 · 6 (6) · 996-1004

DOI: 10.21873/cdp.10602 ↗
AbstractBibliografische Angaben

Abstract

Background/Aim: α-Enolase (ENO1) is a glycolytic enzyme that also functions as a plasminogen receptor when translocated to the cell surface, where it promotes extracellular matrix degradation and invasion. The surface and cytosolic functions of ENO1 is therefore distinct, but whether they differ in prognostic value in lung adenocarcinoma (LUAD) is unknown. This study evaluated the prognostic value of surface and cytosolic ENO1 in LUAD. Patients and Methods: Surface and cytosolic ENO1 were assessed by immunohistochemistry in 174 LUAD patients and stratified as low or high according to the median H-score. The relationship between ENO1 expression and clinicopathological parameters was analyzed, and 5-year overall survival (OS) and progression-free survival (PFS) were evaluated. Results: High surface ENO1 expression was associated with older age (p=0.044), nodal metastasis (p=0.030), and poor tumor differentiation (p=0.017). Patients with high surface ENO1 had significantly worse 5-year OS (64.0% vs. 80.1%, p=0.041) and 5-year PFS (44.8% vs. 65.0%, p=0.047). In univariate analysis, high surface ENO1 was associated with an increased risk of 5-year OS [hazard ratio (HR)=1.94, 95% confidence interval (CI)=1.02-3.71] and 5-year PFS (HR=1.62, 95%CI=1.00-2.63). In contrast, cytosolic ENO1 was not associated with any clinicopathological parameter or survival outcome. Conclusion: Surface, but not cytosolic, ENO1 is associated with adverse pathological features and poor survival in LUAD. These results suggest that the surface pool is the prognostically relevant fraction of ENO1 and support its evaluation as a biomarker and therapeutic target in LUAD.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →